Equities Analysts Set Expectations for Blueprint Medicines Co.’s FY2027 Earnings (NASDAQ:BPMC)

Blueprint Medicines Co. (NASDAQ:BPMC) – Equities researchers at Leerink Partnrs issued their FY2027 earnings estimates for Blueprint Medicines in a research report issued to clients and investors on Monday, May 6th. Leerink Partnrs analyst A. Berens forecasts that the biotechnology company will post earnings of $5.34 per share for the year. Leerink Partnrs currently has a “Market Perform” rating on the stock. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($5.38) per share.

Blueprint Medicines (NASDAQ:BPMC) last posted its earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) EPS for the quarter, topping analysts’ consensus estimates of ($2.04) by $0.22. The business had revenue of $71.96 million during the quarter, compared to the consensus estimate of $67.34 million. Blueprint Medicines had a negative net margin of 102.15% and a negative return on equity of 193.48%. The firm’s revenue was up 85.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($2.65) EPS.

Several other equities research analysts have also commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $97.00 price target on shares of Blueprint Medicines in a research report on Thursday, May 2nd. Wedbush reiterated an “outperform” rating and issued a $110.00 price target on shares of Blueprint Medicines in a research report on Friday, April 26th. Barclays upped their price objective on Blueprint Medicines from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Friday, May 3rd. StockNews.com upgraded Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Friday, May 3rd. Finally, Piper Sandler upped their price target on Blueprint Medicines from $78.00 to $104.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Two research analysts have rated the stock with a sell rating, six have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $100.31.

Blueprint Medicines Stock Performance

Shares of BPMC opened at $108.55 on Tuesday. Blueprint Medicines has a one year low of $43.89 and a one year high of $110.93. The business has a fifty day moving average of $92.17 and a 200 day moving average of $81.81. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.76 and a quick ratio of 3.61. The firm has a market capitalization of $6.64 billion, a P/E ratio of -22.57 and a beta of 0.65.

Institutional Investors Weigh In On Blueprint Medicines

Large investors have recently bought and sold shares of the business. PNC Financial Services Group Inc. grew its stake in shares of Blueprint Medicines by 63.4% in the 3rd quarter. PNC Financial Services Group Inc. now owns 848 shares of the biotechnology company’s stock worth $43,000 after buying an additional 329 shares in the last quarter. Cutler Group LLC CA grew its position in Blueprint Medicines by 1,685.7% in the third quarter. Cutler Group LLC CA now owns 1,000 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 944 shares in the last quarter. Compass Wealth Management LLC purchased a new position in shares of Blueprint Medicines during the fourth quarter valued at approximately $69,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Blueprint Medicines by 95.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,550 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 757 shares during the last quarter. Finally, Van ECK Associates Corp raised its holdings in shares of Blueprint Medicines by 28.4% in the fourth quarter. Van ECK Associates Corp now owns 872 shares of the biotechnology company’s stock worth $80,000 after buying an additional 193 shares during the period.

Insider Buying and Selling

In other Blueprint Medicines news, Director Jeffrey W. Albers sold 25,073 shares of the business’s stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $87.28, for a total value of $2,188,371.44. Following the sale, the director now owns 176,050 shares in the company, valued at approximately $15,365,644. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Blueprint Medicines news, CFO Michael Landsittel sold 13,734 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $87.78, for a total transaction of $1,205,570.52. Following the completion of the transaction, the chief financial officer now owns 47,286 shares in the company, valued at approximately $4,150,765.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeffrey W. Albers sold 25,073 shares of Blueprint Medicines stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $87.28, for a total value of $2,188,371.44. Following the completion of the sale, the director now directly owns 176,050 shares in the company, valued at approximately $15,365,644. The disclosure for this sale can be found here. Over the last quarter, insiders sold 104,123 shares of company stock worth $9,554,679. 3.88% of the stock is owned by insiders.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.